Xilio Therapeutics, Inc. beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | — | $-0.33 | — | Miss |
| Q12026 FY2026 | $-0.66 | $-0.58 | +12.1% | Beat |
| Q42025 FY2025 | $-1.68 | $-0.85 | +49.4% | Beat |
Back to XLO overview · XLO holders · XLO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.